Q3 Earnings Forecast for FULC Issued By Leerink Partnrs

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) – Equities researchers at Leerink Partnrs lowered their Q3 2025 earnings estimates for shares of Fulcrum Therapeutics in a report issued on Tuesday, July 29th. Leerink Partnrs analyst J. Schwartz now forecasts that the company will earn ($0.34) per share for the quarter, down from their prior forecast of ($0.30). Leerink Partnrs has a “Strong-Buy” rating on the stock. The consensus estimate for Fulcrum Therapeutics’ current full-year earnings is ($0.16) per share. Leerink Partnrs also issued estimates for Fulcrum Therapeutics’ Q4 2025 earnings at ($0.34) EPS, FY2025 earnings at ($1.24) EPS, Q1 2026 earnings at ($0.34) EPS, Q2 2026 earnings at ($0.33) EPS, Q3 2026 earnings at ($0.33) EPS, Q4 2026 earnings at ($0.33) EPS, FY2026 earnings at ($1.33) EPS and FY2027 earnings at ($1.17) EPS.

Several other brokerages have also recently issued reports on FULC. Leerink Partners upgraded Fulcrum Therapeutics from a “market perform” rating to an “outperform” rating and lifted their price objective for the company from $4.00 to $12.00 in a research note on Friday, May 23rd. Cantor Fitzgerald upgraded shares of Fulcrum Therapeutics from a “neutral” rating to an “overweight” rating and set a $10.00 price target for the company in a research note on Thursday, May 15th. Royal Bank Of Canada boosted their price target on shares of Fulcrum Therapeutics from $4.00 to $5.00 and gave the stock a “sector perform” rating in a report on Wednesday. HC Wainwright raised shares of Fulcrum Therapeutics from a “neutral” rating to a “buy” rating and increased their price objective for the company from $4.00 to $12.00 in a research report on Tuesday. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $9.00 price objective (up from $6.00) on shares of Fulcrum Therapeutics in a research report on Thursday, May 29th. One analyst has rated the stock with a sell rating, two have issued a hold rating, four have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $7.57.

Fulcrum Therapeutics Price Performance

FULC opened at $6.83 on Friday. The business has a fifty day moving average price of $7.17 and a 200 day moving average price of $4.99. Fulcrum Therapeutics has a 12 month low of $2.32 and a 12 month high of $10.13. The stock has a market capitalization of $369.43 million, a price-to-earnings ratio of -5.60 and a beta of 2.47.

Fulcrum Therapeutics (NASDAQ:FULC) last posted its quarterly earnings data on Tuesday, July 29th. The company reported ($0.28) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.01.

Institutional Trading of Fulcrum Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in FULC. Jump Financial LLC acquired a new position in shares of Fulcrum Therapeutics in the 1st quarter valued at $30,000. Brooklyn Investment Group lifted its position in Fulcrum Therapeutics by 209.7% in the first quarter. Brooklyn Investment Group now owns 12,190 shares of the company’s stock valued at $35,000 after acquiring an additional 8,254 shares during the last quarter. BNP Paribas Financial Markets acquired a new position in Fulcrum Therapeutics in the fourth quarter valued at $38,000. Virtu Financial LLC purchased a new position in shares of Fulcrum Therapeutics during the first quarter worth about $39,000. Finally, Mariner LLC purchased a new position in shares of Fulcrum Therapeutics during the fourth quarter worth about $78,000. Institutional investors and hedge funds own 89.83% of the company’s stock.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.